Generics 18

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Dexmedetomidine hydrochloride manufacturers

18 products found

Filters

18 products found

dexmedetomidine hydrochloride

Solution for infusion 400 mcg/100 mL (4 mcg/mL) in 0.9% Sodium Chloride

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
United States
GMP approvals
FDA
Manufacturer #17737

Manufacturer usually replies in 5 days

dexmedetomidine hydrochloride

Solution for injection 0.2 mg , 0.1 mg - 2 ml , 1 ml , 50 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
China
Manufacturer #12677

Manufacturer usually replies in 4 days

dexmedetomidine hydrochloride

Solution for injection 200 mcg/2 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP
Manufacturer #13095

Manufacturer usually replies in 5 days

dexmedetomidine hydrochloride

Vials, injection 100 mcg/ml - 1 ml, 2 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #2303

Manufacturer usually replies in 7 days

dexmedetomidine hydrochloride

Vials, injection 200 mcg/2 ml - 2 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
PICS, EU GMP
Manufacturer #2272
The company integrates and applies enormous experience and technology in the field of hospital products. Their goal is to become a global leader in intensive care units and maintain that position. The company's headquarters were established in Europe in 1980ies, and serum production was continuing in a plant in Europe till the end of the 2000s. With a nationwide market share of 50%, it has become one of the leading serum producers. They've already started making the first ready-to-use injections.

Manufacturer usually replies in 7 days

dexmedetomidine hydrochloride

Ampoules, injection 100 mcg/ml - 2 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Available for
Licensing with supply, Distribution only
Manufacturer #18885

Manufacturer usually replies in 7 days

dexmedetomidine hydrochloride

Vials, injection 236 mcg / 2 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
South Korea
GMP approvals
PICS
Manufacturer #18072
It is a pharmaceutical company committed to importing, exporting, manufacturing, and distributing innovative drugs to fulfill unmet medical needs. They started the business in the 1990s targeting the niche market for the treatment of urinary stones and cystitis. After initial success in the urologic field, they are expanding the scope of service to Gastrointestinal/General Surgery, Ob-Gyn, orthopedics, oncology, and immunology and are growing in average revenue by more than 43% every year since the 2000s.

Manufacturer usually replies in 5 days

dexmedetomidine hydrochloride

Concentrate for solution for infusion 100mcg/ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Sweden , Denmark , Norway , Finland , Germany , United Kingdom
Available for
Licensing with supply, Distribution only
Manufacturer #12980
It is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain to be able to deliver cost-efficient medicines of the highest quality to pharmacies and hospitals, primarily in the Nordic region. The company conducts extensive development activities in collaboration with partners in Asia, Europe, and India. The strategy is to develop generic medicines in areas where the competition is limited, so-called niche generics. The entire business is based on delivering the cheapest medicines to pharmacies and hospitals, in this way daily lowering the cost of high-quality drugs for patients and society.

Manufacturer usually replies in 14 days

dexmedetomidine hydrochloride

Solution for injection 200 mcg/2 ml

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
FDA
Manufacturer #13095

Manufacturer usually replies in 5 days

dexmedetomidine hydrochloride

Bags for injection/infusion 4 mcg/ml - 50 ml, 100 ml

Dossier type
US CTD
Dossier status
Under development
Country of origin
India
GMP approvals
FDA
Comments
ANDA / R &D Status: ANDA to be filed in Q3-2023, approval expected Q3-2024; US RLD / Holder: "Precedex / Hospira "; Indication: Highly selective α2-adrenergic receptor agonist. Sedation of initially intubated and mechanically ventilated patients
Manufacturer #8216

Manufacturer usually replies in 6 days

dexmedetomidine hydrochloride

Vials, injection Upon request

Dossier type
CTD
Dossier status
Ready to file
Country of origin
South Korea
GMP approvals
PICS
Manufacturer #18007
The objective of the company is to deliver health to all who desire the hands of therapeutic care. This implies the integration of both the goals of the employees and the management philosophy based on a great store of experiences and the customer's fullest trust. The company has received major recognition and awards in recent times.

Manufacturer usually replies in 5 days

dexmedetomidine hydrochloride

Vials, injection 0.118 mg / ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
South Korea
GMP approvals
PICS
Manufacturer #18007
The objective of the company is to deliver health to all who desire the hands of therapeutic care. This implies the integration of both the goals of the employees and the management philosophy based on a great store of experiences and the customer's fullest trust. The company has received major recognition and awards in recent times.

Manufacturer usually replies in 5 days

dexmedetomidine hydrochloride

Solution for injection 50 mcg/0,5ml, 100 mcg/ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Available for
Licensing with supply
Manufacturer #10323

Manufacturer usually replies in 5 days

dexmedetomidine hydrochloride

Vials, injection 200 μg/2 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
PICS
Manufacturer #13095

Manufacturer usually replies in 5 days

dexmedetomidine hydrochloride

Solution for injection 100mcg/ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #9558

Manufacturer usually replies in 10 days

dexmedetomidine hydrochloride

Injection 200mcg/2ml, 80mcg/20ml ,200mcg/50ml ,400mcg/100ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
FDA, TGA
Manufacturer #17216

Manufacturer usually replies in 19 days

dexmedetomidine hydrochloride

Injection 25 mcg, 50 mcg, 100 mcg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19912

Manufacturer usually replies in 18 days

dexmedetomidine hydrochloride

Injection 0.2 mg - 2 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
China
Manufacturer #31064

What is DEXMEDETOMIDINE HYDROCHLORIDE?

Dexmedetomidine is a pharmaceutical substance that is sold under the trade name Precedex amongst others, is an anxiety-reducing, sedative, and pain medicine. This pharmaceutical drug is well-known for its capacity to provide sedation outdoors risk of respiratory depression (unlike other generally used drugs such as propofol and fentanyl) and can provide usefulness or semi-rousable sedation. Similar to clonidine, it is a sympatholytic drug that acts as an agonist of α2-adrenergic receptors insecure parts of the cerebrum. Veterinarians use dexmedetomidine for comparable purposes in treating kittens, dogs, and horses. It was revealed by Orion Pharma. Dexmedetomidine is everywhere frequently practiced in the intensive care setting for light to modest sedation. It is not approved for long-term heartfelt sedation. A biography of dexmedetomidine is that it has analgesic characteristics in addition to its capacity as an anesthetic, but is opioid-sparing; thus, it is not associated with significant respiratory difficulty(unlike propofol). Many studies recommend dexmedetomidine for sedation in mechanically ventilated adults may reduce the time to extubation and ICU sojourn. Characters on dexmedetomidine can be rousable and cooperative, an advantage in some schemes. Compared amidst other sedatives, some considerations suggest dexmedetomidine may be associated with less delirium. Nevertheless, this finding is not compatible across multiple schoolrooms. At the very least, when aggregating many study decisions together, the use of dexmedetomidine resembles to be associated with less neurocognitive dysfunction examined to other sedatives. Whether this observation has a beneficial psychological impact is unclear. From an economic perspective, this pharmaceutical medicine is associated with lower ICU costs, mainly due to a more diminutive time to extubation. Intravenous immersion of dexmedetomidine is commonly initiated with a loading dose followed by a continuance infusion. There may be great individual variability in the hemodynamic effects (especially on heart rate and blood pressure), as well as the sedative effects of this drug. For this reason, the dose must be carefully adjusted to achieve the desired clinical effect. There is no absolute contraindication to the use of dexmedetomidine. It has a biphasic effect on blood pressure with lower sections at lower drug combinations and higher readings at higher intensities. Rapid IV administration or bolus has been associated with hypertension due to peripheral α2-receptor stimulation. Bradycardia can be a limiting factor with infusions, especially in higher doses.

How does it DEXMEDETOMIDINE HYDROCHLORIDE work?

Similar to clonidine, it is a sympatholytic medication that functions as an agonist of α2-adrenergic receptors in particular parts of the brain. Veterinarians use dexmedetomidine for similar purposes in treating cats, dogs, and horses.

The Wholesale Price of DEXMEDETOMIDINE HYDROCHLORIDE

The cost for dexmedetomidine intravenous solution (4 mcg/mL-NaCl 0.9%) is around $228 for a supply of 200 milliliters, depending on the pharmacy you visit.

Sourcing DEXMEDETOMIDINE HYDROCHLORIDE Manufacturers and Suppliers

PipelinePharma has found 7 verified dexmedetomidine hydrochloride manufacturers and dexmedetomidine hydrochloride suppliers from our global list of sellers. The pharmaceutical drug is available for sale in various forms such as injection, solution for injection, vials, ampoules from manufacturers in various countries including China, India, Turkey.

Navigating our pharmaceutical marketplace

PipelinePharma is a global B2B pharmaceutical online marketplace. Pipelinepharma is structured so as to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of dexmedetomidine hydrochloride offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms.